More than 5,00,000
implants in more than
75 countries
Very low event rates in all comers Randomized Controlled Trial (RCT) at 1 year.
More than 5,00,000
Designed for flexibility,
radial strength and distal delivery
Flexible ‘S’ connector
Open cell design
Out of phase rings
Clinically proven, safe and effective drug Sirolimus elutes from biodegradable polymeric matrix
Outstanding Clinical Trial Outcomes
Scientific evidence on Supraflex & Supra family has covered more than 20,000 patients till date. Supraflex is a comprehensively evaluated brand on several clinical parameters right from Randomized Controlled Trial (RCT), First in Man, Pharmacokinetic Studies, Recoil Studies, OCT Studies to Real World Patient Registries. The well conducted and scientifically designed studies on Supra family of products have ensured that the results of the clinical trials have been accepted, presented and published in best of the scientific congress and world’s most prestigious indexed journals.
“In the per-protocol analysis of our study (appendix), Supraflex showed a 20% relative risk reduction in device-oriented composite endpoint at 1 year, mainly driven by a 61% reduction in clinically indicated target lesion revascularization.” – text from The Lancet.
Randomized Controlled Trial (RCT) Supraflex vs Xience Family 1 year Results in All-comers European Patient Population
CI-TLR = Clinically Indicated Target Lesion Revascularization, DOCE = Device-Oriented Composite Endpoint, TLF = Target Lesion Failure,
ST = Definite or Probable Stent Thrombosis, RCT = Randomized Controlled Trial
Quotes from the publication1
"In the per-protocol analysis of our study (appendix), Supraflex showed a 20% relative risk reduction in device-oriented composite endpoint at 1 year, mainly driven by a 61% reduction in clinically indicated target lesion revascularisation."
"Definite or probable stent thrombosis prevalence, a safety indicator, was low in both groups and did not differ between them."
"Per-protocol analysis showed a significantly lower clinically indicated target lesion revascularisation in the Supraflex group than in the Xience group."
"Definite or probable stent thrombosis prevalence, a safety indicator, was low in both groups and did not differ between them."
"Per-protocol analysis showed a significantly lower clinically indicated target lesion revascularisation in the Supraflex group than in the Xience group."
Now published in
British Medical Journal2
FlexRegistry
FLEX registry reveals a low rate of clinical events across a wide range of unselected patients.
Supraflex SES (n=995)
6 months strut coverage
Favourable Healing Index
D: Days M: Months
Complete Size Matrix
1. Zaman, Azfar et.al. The Lancet, Volume 393, Issue 10175, 987 - 997
2. Lemos PA, et. al. BMJ open 2016;6:e010028. doi:10.1136/bmjopen-2015-010028
Supraflex is a registered trademark of Sahajanand Medical Technologies Ltd. or its affiliates. Specifications are subject to modification, revision and improvement.
BioFreedom and BioMatrix Alpha are trademarks of Biosensors International. Xience V, Xience Alpine, Xience Prime, Xience Xpedition and Xience Sierra are trademarks of the Abbott Group of Companies. Resolute Onyx is a trademark of Medtronic, Inc or it's affiliates. Synergy is a trademark of Boston Scientific Corporation or its affiliates. Ultimaster is a trademark of Terumo Corporation. Orsiro is a trademark of Biotronik SE.